David has had a long career building a number of science, technology and investment companies. He is the founder of IP Group plc, one of the UK’s leading technology commercialisation businesses and a shareholder in the Company. Previously, he was Chief Executive of stockbroker Beeson Gregory (acquired by Evolution Group plc) after it acquired IndexIT Partnership, a technology advisory boutique he had founded in 1999. He was a founding shareholder of Evolution Group plc (recently acquired by Investec), and also co-founder of Ora Capital plc. He has been a founder and director of many UK technology companies including Oxford Nanopore Technologies Ltd, Proximagen Ltd, Synairgen plc, Ilika Technologies Ltd, Oxford Catalysts and Plectrum Petroleum (acquired by Cairn Energy plc). He has also acted as seed investor and/or advisor to Wolfson Microelectronics Ltd, Nanoco Technologies Ltd, Tissue Regenix Group plc and Arc International (now part of Synopsys). He is also Non-Executive Chairman of Oxford Pharmascience Group plc.

Duncan has a proven track record in identifying, investing and growing business within the pharmaceutical sector. He was the founder of Aquarius Equity, a specialist investor in businesses within the life science sector, which provided investors’ access to innovative, high growth potential companies that delivered significant capital growth. Duncan started his career in a bio-science start-up business, which ultimately went on to list on the London Stock Exchange, subsequently qualified as a corporate finance lawyer with Addleshaw Goddard, then Addleshaw Booth & Co, and later joined 3i plc as an investment manager. Duncan founded Aquarius in 2005, which made founding investments into Nanoco Technologies Ltd, Auralis Limited (subsequently sold to ViroPharma) and Tissue Regenix Group plc.

Alex began his career as a scientist, working in research and for a NYSE quoted drug development company, before moving into early-stage pharmaceutical and healthcare investments. He has fulfilled board level investment and operational management roles. He was a director and shareholder in Aquarius Equity from 2008, where he was responsible for identifying new investments and developing and implementing scientific strategies both pre and post-investment. Prior to joining Aquarius Equity, Alex worked for IP Group plc where he specialised in life science investments, identifying, developing and advising a number of companies in its portfolio, some of which went on to list on AIM. He joined IP Group following its acquisition of Techtran Group Ltd in 2005.

Thomas is also non executive chairman at Akcros Holdings Ltd, Penlan Healthcare and Quantum Pharmaceutical. Thomas has been a founder and/or non-executive director of a number of UK life sciences companies including Colonis Pharma Ltd, Warneford Partners Ltd and Martindale Pharma Ltd. Thomas has supported private equity and other investors in over 50 potential deal transactions, on targets in Europe and the USA, from cash constrained/chapter 11 to cash-rich with EV of up to $1 billion. Before this Thomas worked in life sciences for over 20 years in senior executive roles. Starting in 1987 at Akzo Nobel Pharma he worked with hospital products, diagnostics and medical equipment as General Manager for Middle East & Africa. After this he led Rosemont Pharmaceuticals in Leeds in niche oral liquid medicines, followed by being President of Organon in Brazil. He was promoted to VP The Americas, and lastly to CMO at Organon, in charge of the global product portfolio, based in the USA. Returning to Europe he led Novartis Consumer Health in the UK.

BACK TO TOP